Source comparison
Sermorelin vs CJC-1295 for GH Research UK 2026
All compounds discussed in this article are research-grade peptides supplied for laboratory and scientific investigation only. This content is intended for researchers, scientists and qualified professionals. No information herein constitutes medical advice, a
This comparison does not assign a generated winner or score.
- All compounds discussed in this article are research-grade peptides supplied for laboratory and scientific investigation only. This content is intended for researchers, scientists and qualified professionals. No information herein constitutes medical advice, and none of these compounds are approved for human therapeutic use in the United Kingdom.
- This comparison examines Sermorelin and CJC-1295 as GHRH receptor agonists — covering angles distinct from our posts on Sermorelin vs rhGH (ID 77460), CJC-1295 vs Ipamorelin (ID 77443), Ipamorelin vs Sermorelin (ID 77160), and the GH secretagogue hub (ID 77059). The specific mechanistic focus here is the Sermorelin-vs-CJC-1295 comparison at the GHRHR itself: how the same receptor produces fundamentally different GH secretion profiles depending on whether it is activated by a short-acting endogenous sequence analogue (Sermorelin, GHRH₁₋₂₉) versus a long-acting DAC-modified peptide (CJC-1295 with DAC), and the downstream consequences for GH pulsatility preservation, IGF-1 plateau versus pulse physiology, somatostatin feedback dynamics, and sex-dimorphic hepatic GH signalling.